News | May 21, 2015

Elekta Earns CE Mark for Monaco v5.10 Treatment Planning System

Latest version supports planning for multiple patients simultaneously across multiple treatment techniques

Elekta, Monaco, v5.10, CE Mark

May 21, 2015 — Elekta has CE marked the latest version (v5.10) of its popular Monaco treatment planning system, enabling its sale to European clinics. The system supports major treatment techniques including advanced 3-D planning, intensity modulated radiation therapy (IMRT), volumetric arc therapy (VMAT) and stereotactic planning – all in a single system.

Monaco v5.10 provides significant planning and quality assurance (QA) enhancements, as well improved workflow efficiency. Advancements in 3-D planning as well as the addition of magnetic resonance imaging (MRI) and forward planning capabilities further reinforces Monaco as a robust and flexible treatment planning solution. Now, users can simplify their planning with advanced time-saving tools, speed up workflow and ultimately create better plans with fewer contours and therefore less variability.

Furthermore, utilizing the Monte Carlo algorithm, Monaco now enables users to recalculate third-party plans for quality assurance checks.

Key Monaco v5.10 benefits designed to improve planning time enable clinicians to:

  • Optimize plan creation with customizable templates that can be shared across institutions;
  • Plan multiple patients simultaneously;
  • Achieve better dose conformity with state-of-the art optimization tools;
  • Create multiple prescriptions within a single active plan; and
  • Quickly learn and use the system through its modern, intuitive interface.


For more information:

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.